A randomized, placebo-controlled, investigator-and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HSY244 in participants with atrial fibrillation
HSY244 to Restore Normal Heart Rhythm in People with Atrial Fibrillation
Sponsor: Novartis Institutes
Enrolling: Male and Female Patients
Clinic Visits: 3
IRB Number: AAAT4851
U.S. Govt. ID: NCT04582409
Contact: Catherine Moore: 212-342-3490 / cjm2285@cumc.columbia.edu
Additional Study Information: A randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HSY244 in participants with AF. Participants will be randomized and assigned to one of the following 2 treatment arms in a ratio of 1:1. Arm 1: HSY244 intravenous infusion; Arm 2: Placebo intravenous infusion. The study consists of a screening period of up to 3 days and a treatment period of 4 days. After confirming eligibility on Day 1 and pre-dose assessments are completed, study administration will occur and participants will be monitored for cardioversion to sinus rhythm. During the treatment period, participants will be evaluated for efficacy, safety, tolerability, and pharmacokinetics.
Investigator
Angelo Biviano, MD, MPH
Do You Qualify?
Are you 18 years or older? Yes No
Are you taking a drug called Amiodarone? Yes No
Have you been diagnosed with Atrial fibrillation? Yes No
Have you ever had seizures, epilepsy or head trauma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Catherine Moore
cjm2285@cumc.columbia.edu
212-342-3490